Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Despite promising preclinical studies with the cyclin-dependent kinase inhibitor flavopiridol in chronic lymphocytic leukemia (CLL) and other diseases, previous clinical trials with this agent have been disappointing. The discovery of differential protein binding of flavopiridol in human and bovine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Byrd, John C., Lin, Thomas S., Dalton, James T., Wu, Di, Phelps, Mitch A., Fischer, Beth, Moran, Mollie, Blum, Kristie A., Rovin, Brad, Brooker-McEldowney, Michelle, Broering, Sarah, Schaaf, Larry J., Johnson, Amy J., Lucas, David M., Heerema, Nyla A., Lozanski, Gerard, Young, Donn C., Suarez, Jose-Ramon, Colevas, A. Dimitrios, Grever, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Plenary Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785084/
https://ncbi.nlm.nih.gov/pubmed/17003373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-05-020735
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados